Topic: How To Invest

What is Pat’s commentary for the week of June 2, 2020

Article Excerpt

Here’s the text of the most-recent letter I sent to our Portfolio Management clients last month: “We’ve generally stayed out of drug stocks for much of the past two decades, but that will change over the next year or two. In fact, we now expect to see many great investment opportunities in drug stocks throughout the 2020s. You could say this is related to COVID-19, but it was going to happen anyway, due to regulatory and research developments that were already underway. COVID-19 simply gives it a boost. Why we held off on drug stocks In the first few years after our 1994 launch of The Successful Investor, we recommended several drug stocks. We agreed with the widespread notion that the drug industry was headed for a boom, if only because the baby boomers were reaching a time in life where they had more age-related health problems. By 1998 or so, we decided drug stock prices were too high in relation to current earnings. These…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.